Trial Profile

Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Guanfacine (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Therapeutic Use
Sponsors Shionogi; Shire

Most Recent Events

14 Apr 2020 Results published in the Journal of Clinical Psychiatry
13 Aug 2018 According to a Shire media release, the company's partener Shionogi & Co., Ltd has submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV (guanfacine hydrochloride extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
13 Aug 2018 Results published in a Shire media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com